From: A cautionary tale: an evaluation of the performance of treatment switching adjustment methods in a real world case study
BSC (n = 232)
Panitumumab plus BSC (n = 231)
MT KRAS
100
84
WT KRAS
119
124
Unknown KRAS
13
23
MT KRAS switchers
77 (23 non-switchers)
-
WT KRAS switchers
91 (28 non-switchers)
Switchers with unknown KRAS
8